International Drug Scheduling: Single Convention on Narcotic Drugs, Convention on Psychotropic Substances; Clobromazolam (phenazolam), Cychlorphine (N-propionitrile chlorphine), etc.
International drug scheduling notice proposes adding clobromazolam, cychlorphine, and other substances to controlled schedules under UN conventions, which may lead to U.S. rescheduling and DEA quota impacts.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 25, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Manufacturers, importers, and distributors of the listed substances (clobromazolam, cychlorphine, etc.) and their supply chains. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified in the excerpt; check the Federal Register notice for comment period and effective dates.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The notice proposes international scheduling of these substances under the Single Convention and Convention on Psychotropic Substances, which typically precedes U.S. rescheduling and DEA quota adjustments.
Who it affects
Manufacturers, importers, and distributors of the listed substances (clobromazolam, cychlorphine, etc.) and their supply chains.
What you must do
Monitor the docket and prepare for potential DEA scheduling changes; review current inventory and supply contracts for affected substances.
Deadline
Not specified in the excerpt; check the Federal Register notice for comment period and effective dates.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- US-CONGRESS BILLS-119hr10133ih: Fair Prescription Pricing Act of 2026
- Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
- FDA declares Novo Nordisk plant, key to drug manufacturing for some biotechs, out of compliance - STAT
- Schering-Plough agrees to pay FDA $500 million and bring factories into compliance - American Veterinary Medical Association
- Florida Company Receives FDA Warning Letter - PharmTech.com